Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network
"The healthcare community understands the importance of tracking and monitoring biomarker status in order to successfully treat cancer patients," said
"We are excited to have
"Through this collaboration with ACPN, we have expanded access to liquid biopsy to 19 million Americans, giving them an option to avoid additional surgeries for a tissue biopsy - thus reducing costs while improving outcomes," added
About
About America's Choice Provider Network
America's Choice Provider Network (ACPN) is an independent, multi-specialty national provider network that offers providers, payers, and patients an out of network solution. Across the nation, greater than 19 million Americans and over 1,100 payers have access to ACPN's proprietary national network through a client base consisting of Insurance Carriers, Third Party Administrators, Health and Welfare Funds, Employer Groups and Self-Insured Health Plans. The products covered include
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the Company's ability to partner with other payors, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
CONTACT: Investor Contact:Source:The Ruth Group David Burke (646) 536-7009 dburke@theruthgroup.com Media Contact:The Ruth Group Melanie Sollid-Penton (646) 536-7023 msollid@theruthgroup.com
News Provided by Acquire Media